Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $2.18, $1.64 worse than the analyst estimate of $3.82. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $84.1 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.